Lin Shao-Lee — SEC insider filings

SEC reporting owner CIK 1725092. 20 insider filings on record with FilingPulse; latest filed 2026-10-14.

Transaction summary — filings shown

Covers all 20 filings on record, filed 2020-09-28 to 2026-10-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Cue Biopharma, Inc. (CUE)Chief Executive Officer, Director6—7 legs · 69,345 sh · $1,912,05310
ACELYRIN, Inc. (SLRN)Chief Executive Officer, Director8—3 legs · 36,353 sh · $264,61624
Surrozen, Inc./DE (SRZN)Director4——4
Principia Biopharma Inc. (PRNB)Director1——3
Third Harmonic Bio, Inc. (THRD)Director1——1

Insider filings — Lin Shao-Lee

FiledFormIssuerReported transactionsSource
2026-10-144Cue Biopharma, Inc. (CUE)Sale (S): 10,000 @ $27.50 · Sale (S): 1,087 @ $28.05EDGAR
2026-08-144Cue Biopharma, Inc. (CUE)Option exercise (M): 109,179 @ $0 · Sale (S): 34,225 @ $26.99 · Sale (S): 5,775 @ $27.75 · Sale (S): 5,423 @ $27.19 · Sale (S): 2,375 @ $28.11 · Sale (S): 10,460 @ $29.48 · +1 moreEDGAR
2026-07-304/ACue Biopharma, Inc. (CUE)Grant/award (A): 90,906 (derivative) @ $11 · Grant/award (A): 45,453 (derivative)EDGAR
2026-07-104Cue Biopharma, Inc. (CUE)Grant/award (A): 327,537 @ $0 · Grant/award (A): 327,537 (derivative) @ $0EDGAR
2026-06-034Cue Biopharma, Inc. (CUE)Purchase (P): 90,906 (derivative) @ $11 · Purchase (P): 45,453 (derivative)EDGAR
2026-05-074Cue Biopharma, Inc. (CUE)Grant/award (A): 327,537 @ $0 · Grant/award (A): 655,074 (derivative) @ $0EDGAR
2025-05-154Surrozen, Inc./DE (SRZN)Grant/award (A): 1,333 (derivative) @ $0EDGAR
2024-06-064Surrozen, Inc./DE (SRZN)Grant/award (A): 1,333 (derivative) @ $0EDGAR
2024-04-034ACELYRIN, Inc. (SLRN)Sale (S): 9,961 @ $6.63EDGAR
2024-02-224ACELYRIN, Inc. (SLRN)Sale (S): 15,701 @ $7.60EDGAR
2024-01-114ACELYRIN, Inc. (SLRN)Grant/award (A): 964,829 (derivative) @ $0 · Grant/award (A): 413,498 (derivative) @ $0EDGAR
2024-01-044ACELYRIN, Inc. (SLRN)Sale (S): 10,691 @ $7.41EDGAR
2023-10-064ACELYRIN, Inc. (SLRN)Other (J): 1,161,747 @ $0 · Other (J): 132,236 @ $0EDGAR
2023-08-184ACELYRIN, Inc. (SLRN)Grant/award (A): 842,400 @ $0EDGAR
2023-05-194Surrozen, Inc./DE (SRZN)Grant/award (A): 20,000 (derivative) @ $0EDGAR
2023-05-114ACELYRIN, Inc. (SLRN)Conversion (C): 1,161,747 · Other (J): 1,107,213 @ $0 · Other (J): 1,107,213 @ $0 · Tax withholding (F): 337,179 @ $24.69 · Other (J): 677,813 @ $0 · Other (J): 677,813 @ $0 · +12 moreEDGAR
2023-05-044ACELYRIN, Inc. (SLRN)Grant/award (A): 774,788 (derivative) @ $0EDGAR
2022-10-274Third Harmonic Bio, Inc. (THRD)Grant/award (A): 13,667 (derivative) @ $0EDGAR
2022-06-094Surrozen, Inc./DE (SRZN)Grant/award (A): 20,000 (derivative) @ $0EDGAR
2020-09-284Principia Biopharma Inc. (PRNB)Disposition to issuer (D): 20,475 (derivative) · Disposition to issuer (D): 10,240 (derivative) · Disposition to issuer (D): 10,240 (derivative)EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1725092 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs